- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: primary sjogren syndrome.
Displaying page 1 of 1.
EudraCT Number: 2014-003140-12 | Sponsor Protocol Number: LEF-HCQinpSS | Start Date*: 2015-09-21 | ||||||||||||||||||||||||||
Sponsor Name:UMC Utrecht | ||||||||||||||||||||||||||||
Full Title: Optimizing DMARD-therapy for primary Sjogren's Syndrome - Leflunomide and Hydroxychloroquine combination therapy for patients with primary Sjogren's Syndrome | ||||||||||||||||||||||||||||
Medical condition: Sjogren's Syndrome | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-003537-16 | Sponsor Protocol Number: PR3084 | Start Date*: 2008-09-04 | |||||||||||
Sponsor Name:Erasmus MC | |||||||||||||
Full Title: Estetrol Therapy in Sjogren's Syndrome: An Open Proof of Concept Study | |||||||||||||
Medical condition: Primary Sjogren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001526-59 | Sponsor Protocol Number: CL2-95011-001 | Start Date*: 2020-10-20 | |||||||||||
Sponsor Name:Institut de Recherches Internationales Servier | |||||||||||||
Full Title: A phase IIa efficacy and safety trial with intravenous S95011 in primary Sjögren’s Syndrome patients. An international, multicentre, randomised, double-blind, placebo-controlled study | |||||||||||||
Medical condition: Primary Sjögren’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Ongoing) DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003298-22 | Sponsor Protocol Number: GLPG3970-CL-207 | Start Date*: 2021-01-15 | |||||||||||
Sponsor Name:Galapagos NV | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3970 for 12 weeks ... | |||||||||||||
Medical condition: Primary Sjogren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-000417-31 | Sponsor Protocol Number: IM101-473 | Start Date*: 2014-07-01 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled phase III study (ASAP III study) to assess the efficacy and safety of Abatacept treatment in patients with primary Sjögren’s syndrome (ASAP III study = ... | |||||||||||||
Medical condition: Primary Sjögren's syndrome (pSS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-015558-40 | Sponsor Protocol Number: ABACEPT1 | Start Date*: 2010-07-28 | |||||||||||
Sponsor Name:University Medical Center Groningen | |||||||||||||
Full Title: Abatacept treatment in patients with primary Sjögren’s syndrome | |||||||||||||
Medical condition: Sjögren’s syndrome (SS) is a chronic, systemic, lymphoproliferative autoimmune disease affecting the exocrine glands. The salivary and lacrimal glands are most commonly affected, resulting in dry m... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013976-38 | Sponsor Protocol Number: COLO400BDE02T | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Charité Berlin, Department of rheumatology [...] | |||||||||||||
Full Title: Phase II Trial of low-dose Sandimmun Optoral ® (Cyclosporine A) for the treatment of primary Sjögren's syndrome (pSS) | |||||||||||||
Medical condition: Primary Sjögren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003292-22 | Sponsor Protocol Number: CVAY736A2201 | Start Date*: 2017-04-06 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of ianalumab doses administered subcutaneously in patients with moderate to s... | |||||||||||||
Medical condition: Primary Sjogren’s syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) PT (Ongoing) GB (GB - no longer in EU/EEA) FR (Completed) NL (Ongoing) HU (Ongoing) BE (Ongoing) AT (Completed) PL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000511-77 | Sponsor Protocol Number: ACT16618 | Start Date*: 2020-11-12 | |||||||||||
Sponsor Name:Sanofi-Aventis Recherche & Développement | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group study of the safety, tolerability, pharmacokinetics, and therapeutic efficacy of SAR441344 in adult patients with primary Sjögren’s ... | |||||||||||||
Medical condition: Sjögren’s syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) HU (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003131-31 | Sponsor Protocol Number: M19-956 | Start Date*: 2020-02-05 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2a, Double-Blind, Randomized, Placebo-Controlled Study of Ravagalimab in Subjects with Moderately to Severely Active Primary Sjogren’s Syndrome. | |||||||||||||
Medical condition: Moderately to Severely Active Primary Sjogren's Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002205-22 | Sponsor Protocol Number: IM014029 | Start Date*: 2020-05-01 | |||||||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||
Full Title: "A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Assess the Efficacy and Safety of Branebrutinib Treatment in Subjects with Active Systemic Lupus Erythematosus or Primary Sjögr... | |||||||||||||||||||||||
Medical condition: SLE Sub-protocol: Systemic Lupus Erythematosus pSS Sub-protocol: Primary Sjögren’s Syndrome RA Sub-protocol: Rheumatoid Arthritis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) ES (Ongoing) PL (Ongoing) DE (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005757-38 | Sponsor Protocol Number: OFTACAMPOS_08_01 | Start Date*: 2009-02-10 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: CORD BLOOD SERUM IN THE TREATMENT OF OCULAR SURFACE DISEASES (PILOT STUDY.) | |||||||||||||
Medical condition: severe ocular surface disorders and the enhancement of corneal wound healing | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000400-26 | Sponsor Protocol Number: 201842 | Start Date*: 2015-12-15 | |||||||||||
Sponsor Name:GlaxoSmithKline R&D Ltd | |||||||||||||
Full Title: A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in su... | |||||||||||||
Medical condition: Primary Sjogrens disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NO (Completed) DE (Completed) ES (Ongoing) NL (Completed) GB (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000372-29 | Sponsor Protocol Number: JBT101-SSc-002 | Start Date*: 2018-03-20 | |||||||||||
Sponsor Name:Corbus pharmaceuticals, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis | |||||||||||||
Medical condition: Systemic Sclerosis (SSc) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Completed) ES (Ongoing) PL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
